News on Medial

Pristyn Care revenue grows 33% to Rs 601 Cr in FY24

Entrackr · 4d

Pristyn Care, a surgery-focused hospital chain, recorded over Rs 600 crore in revenue for the fiscal year ending March 2024. While expanding its operations, the Tiger Global-backed company kept its losses steady during the same period. Pristyn Care’s revenue from operations grew by 32.7% to Rs 601 crore in FY24 from Rs 453 crore in FY23, its consolidated financial statements accessed from the Registrar of Companies show. The company follows a hybrid model, setting up its own clinics and utilizing third-party hospital infra to provide surgeries. The company claims to have a presence in over 40 cities, managing 100 clinics and treating patients in more than 350 partner hospitals. Income from the sale of healthcare services accounted for 55.24% of the total operating revenue which stood at Rs 332 crore in FY24. The rest of the revenue came from the sale of medical and healthcare products which surged 2.5X to Rs 267 crore in the previous fiscal. Pristyn Care also added Rs 31 crore in income from (non-operating) activities, which tallied its overall revenue to Rs 632 crore in FY24, as compared to Rs 494 crore in FY23. For the healthcare firm, the procurement of medical devices accounted for 26% of its total expenses. Driven by the growth in device sales, the procurement costs rose to Rs 264 crore in FY24 from Rs 75 crore in FY23. The company cut its advertising and employee benefits costs by 21% and 3.5% to Rs 183 crore and Rs 192 crore, respectively. Surgery, fees to doctors, legal, travel, consumables, and other overheads increased the overall expenditure to Rs 1,014 crore in FY24 from Rs 877 crore in FY23. By the end of FY24, the Harsimarbir Singh-led company reduced its workforce by 7% as it aims for profitability and prepares for an initial public offering (IPO) in the coming years. The 32% scale and controlled expenditure on advertising and employee benefits helped Pristyn Care to post a flat loss which stood at Rs 381 crore in FY24, as compared to Rs 383 crore in FY23. On a unit level, it spent Rs 1.69 to earn a rupee in FY24. For its surgery business, the company projects a 35% growth in FY25, along with a 60% improvement at the EBITDA level. Pristyn Care also plans to launch an IPO within the next three years. Notably, Pristyn Care achieved this growth without raising external funds in the past three years. In December 2021, the company secured $85 million from Peak XV Partners, Tiger Global to attain unicorn status. In June 2022, it acquired Lybrate, a company backed by Ratan Tata and Tiger Global.